Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

192 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ibrutinib in combination with rituximab is highly effective in treatment of chronic lymphocytic leukemia patients with steroid refractory and relapsed autoimmune cytopenias.
Nikitin E, Kislova M, Morozov D, Belyakova V, Suvorova A, Sveshnikova J, Vyscub G, Matveeva I, Shirokova M, Shipaeva A, Klitochenko T, Makarovskaya P, Dmitrieva E, Biderman B, Sudarikov A, Obukhova T, Samoilova O, Kaplanov K, Konstantinova T, Mayorova O, Poddubnaya I, Ptushkin V. Nikitin E, et al. Leukemia. 2023 Jul;37(7):1464-1473. doi: 10.1038/s41375-023-01891-3. Epub 2023 May 18. Leukemia. 2023. PMID: 37202442 Free PMC article.
Impact of venetoclax monotherapy on the quality of life of patients with relapsed or refractory chronic lymphocytic leukemia: results from the phase 3b VENICE II trial.
Cochrane T, Enrico A, Gomez-Almaguer D, Hadjiev E, Lech-Maranda E, Masszi T, Nikitin E, Robak T, Weinkove R, Wu SJ, Sail KR, Pesko J, Pai M, Komlosi V, Anderson MA. Cochrane T, et al. Among authors: nikitin e. Leuk Lymphoma. 2022 Feb;63(2):304-314. doi: 10.1080/10428194.2021.1986217. Epub 2021 Oct 11. Leuk Lymphoma. 2022. PMID: 34632935 Clinical Trial.
COVID-19 in patients with chronic lymphocytic leukemia: a Moscow observational study.
Kochneva ОL, Kislova M, Zhelnova EI, Petrenko AA, Baryakh EA, Yatskov KV, Dmitrieva EA, Misurina EN, Nikitin KE, Vasilieva EJ, Samsonova IV, Ptushkin VV, Baranova A, Nikitin EA. Kochneva ОL, et al. Among authors: nikitin ke, nikitin ea. Leuk Lymphoma. 2022 Jul;63(7):1607-1616. doi: 10.1080/10428194.2022.2034157. Epub 2022 Feb 13. Leuk Lymphoma. 2022. PMID: 35156528
[Multiple myeloma: response to treatment and survival of patients according to the interim analysis of the Russian observational, retrospective-prospective, multicenter cohort study (MULTISPECT)].
Ptushkin VV, Kunst MA, Mitina TA, Konstantinova TS, Rachkova NN, Shelekhova TV, Elykomov IV, Kuchma GB, Farizova KO, Vinogradova OY, Nikitin EA, Pashanov ED. Ptushkin VV, et al. Among authors: nikitin ea. Ter Arkh. 2022 Aug 12;94(7):827-835. doi: 10.26442/00403660.2022.07.201718. Ter Arkh. 2022. PMID: 36286939 Russian.
Updated quality of life data from the phase 3b VENICE II trial: patients with relapsed or refractory chronic lymphocytic leukemia receiving venetoclax monotherapy.
Cochrane T, Enrico A, Gomez-Almaguer D, Hadjiev E, Lech-Maranda E, Masszi T, Nikitin E, Robak T, Weinkove R, Wu SJ, Manzoor BS, Busman T, Pai M, Komlosi V, Anderson MA. Cochrane T, et al. Among authors: nikitin e. Leuk Lymphoma. 2023 Aug 25:1-4. doi: 10.1080/10428194.2023.2247511. Online ahead of print. Leuk Lymphoma. 2023. PMID: 37626019 No abstract available.
192 results